Allotera Therapeutics

Allotera Therapeutics (formerly Wugen, Inc.) is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies. The company utilizes a proprietary CRISPR/Cas9 gene-editing platform to engineer healthy donor-derived T cells, aiming to overcome limitations of first-generation therapies such as fratricide and graft-versus-host disease (GvHD). Headquartered in St. Louis, Missouri, the company is currently advancing its lead candidate, Soficabtagene Geleucel (Sofi-cel), through a global pivotal clinical trial (T-RRex) for relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Allotera has received significant regulatory support, including RMAT, Breakthrough Therapy, and Orphan Drug designations from the FDA.